Skip to content
2000
Volume 18, Issue 2
  • ISSN: 1573-4021
  • E-ISSN:

Abstract

The practice of angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers (ACEi/ARB) in COVID-19 hypertensive patients is still an open question for clinicians to answer. The present study was conducted to find out the association between the use of ACEI/ARB and the mortality rate of COVID-19 patients. The search was conducted from December 2019 to October 2020 in PubMed to identify relevant published studies. RevMan 5 was used for the analysis of the data. The random-effect model was used to calculate the odds ratio. In total, 07 studies were found to be appropriate, reporting a total of 1,566 subjects. The odds ratio was found to be 0.86 [0.41, 1.81], indicating no association between ACEI/ARB and the mortality rate of COVID- 19 patients. In conclusion, we may suggest continuing the use of ACEi/ARB in COVID-19 patients till further pieces of evidence are generated.

Loading

Article metrics loading...

/content/journals/chyr/10.2174/1573402118666220407093332
2022-08-01
2024-11-07
Loading full text...

Full text loading...

/content/journals/chyr/10.2174/1573402118666220407093332
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test